US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group Co., Ltd, (HKG: 1099) a leading Chinese pharmaceutical company, to improve access to novel drugs and explore standardized patient management practices in China.
Expanding Access and Patient Support
The collaboration will utilize Sinopharm’s extensive SPS+ professional pharmacy network to enhance the distribution and accessibility of innovative medications. The partnership aims to provide patients with rational and safe medication guidance, long-term disease management, and science education, thereby improving disease management capabilities and the overall quality of life for patients. The agreement does not disclose any financial details.
Standardized Patient Management Model
AbbVie and Sinopharm will focus on developing a standardized atopic dermatitis (AD) patient management model, complemented by diversified patient support initiatives. These include medication guidance, follow-up management, and disease knowledge education. The partnership also seeks to secure reasonable and safe medication options, enhance pharmacist service capabilities, and offer comprehensive disease solutions to patients.
Rinvoq’s Market Approval and Indications
AbbVie’s JAK inhibitor Rinvoq (upadacitinib), a blockbuster drug, received marketing approval in China in 2022 for indications that include AD, rheumatoid arthritis, psoriatic arthritis, axial spinal arthritis, and ankylosing spondylitis. This approval marks a significant milestone in the treatment of these conditions in China, offering patients a new therapeutic option.
